NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Idebenone for treating Duchenne muscular dystrophy ID1092

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
	11 /
Company	General
Santhera Pharmaceuticals (idebenone)	All Wales Therapeutics and Toxicology
D .:/	Centre
Patient/carer groups	Allied Health Professionals Federation
Action on Pain Action Duckspan	Board of Community Health Councils in
Action Duchenne Action for Siels Children	Wales
Action for Sick Children Aleyle Wiek	British National Formulary Care Quality Commission
Alex's WishArthritis & Musculoskeletal Alliance	Care Quality Commission Department of Health Social Soci
0 (5 "	 Department of Health, Social Services and Public Safety for Northern Ireland
Contact a FamilyDisability Rights UK	Healthcare Improvement Scotland
 Disability Rights OR Duchenne Family Support Group 	Medicines and Healthcare products
Duchenne Now	Regulatory Agency
Duchenne Research Fund	 National Association of Primary Care
Duchenne UK	National Pharmacy Association
Genetic Alliance UK	NHS Alliance
Harrison's Fund	NHS Commercial Medicines Unit
Information Advice and Support	NHS Confederation
Service Network	Scottish Medicines Consortium
Leonard Cheshire Disability	National Services division for Scotland
Muscular Dystrophy UK	Welsh Health Specialised Services
Muslim Council of Britain	Committee
National Children's Bureau	
South Asian Health Foundation	Possible comparator companies
Specialised Healthcare Alliance	None
Together for Short Lives	Relevant research groups
	British Myology Society
Professional groups	Cochrane Cystic Fibrosis and Genetic
 Association of Anaesthetists of Great Britain & Ireland 	Disorders Group
Association of British Neurologists	Cochrane Musculoskeletal Group
Association of British Neurologists Association of Genetic Nurses &	John Walton Centre for Muscular
Counsellors	Dystrophy (Newcastle University)
Association of Respiratory Nurse	MRC Centre for Neuromuscular
Specialists	Diseases
,	MRC Clinical Trials Unit

National Institute for Health and Care Excellence

Provisional matrix for proposed appraisal of idebenone for treating Duchenne muscular dystrophy [ID1092] Issue date: November 2019 Page 1 of 4

Consultees	Commentators (no right to submit or appeal)
 Association of Surgeons of Great Britain and Ireland British Cardiovascular Society British Dietetic Association British Institute of Musculoskeletal Medicine British Paediatric Neurology	National Institute for Health Research TREAT-NMD Associated Public Health Groups Public Health England Public Health Wales
NHS West London CCGWelsh Government	

Appendix C

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do share it. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland;; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company commentators are invited to nominate clinical or patient experts.

-

¹ Non company consultees are invited to submit statements relevant to the group they are representing.